Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Large Dose DPI

Disposable DPI for high dose drug delivery.

Page
Read more

OWN it! Training and Development Needs FY24

Take an active role in your personal development. Follow the new process to identify, plan and own your training and development needs for FY24.

Page
Read more

Drug Product Manufacturing

To extend Hovione further we are now able to offer clinical supplies manufacturing for drug products.

Page
Read more